# Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

> **NCT00402766** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Imatinib Mesylate
- **DRUG:** Pemetrexed
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00402766
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2015-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402766, "Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00402766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*